A final appraisal determination was issued by the National Institute for Health and Care Excellence approving the use of Bayer’s Xarelto, or rivaroxaban, to prevent atherothrombotic events in adults diagnosed with symptomatic peripheral artery disease or coronary artery disease. Results from the late-stage COMPASS study became the basis for the approval.
NICE approves Xarelto to prevent atherothrombotic events in adults
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.